

the antibody retains at least 95% of the potency of the antibody, or the antigen-binding portion thereof, prior to storage.

22. The pharmaceutical formulation claim **2**, wherein after 18 months of storage at 2-8° C., at least 96% of the antibody, or the antigen-binding portion thereof, has native conformation, at least 50% of the antibody, or the antigen-binding portion thereof, is the main charge variant, and/or the antibody retains at least 95% of the potency of the antibody, or the antigen-binding portion thereof, prior to storage.

23. The pharmaceutical formulation claim **2**, wherein after 18 months of storage at 2-8° C., at least 98% of the antibody, or the antigen-binding portion thereof, has native conformation, at least 55% of the antibody, or the antigen-binding portion thereof, is the main charge variant, and/or the antibody retains at least 95% of the potency of the antibody, or the antigen-binding portion thereof, prior to storage.

24. The pharmaceutical formulation claim **2**, wherein after 24 months of storage at 2-8° C., at least 94% of the antibody, or the antigen-binding portion thereof, has native conformation, at least 45% of the antibody, or the antigen-binding portion thereof, is the main charge variant, and/or the antibody retains at least 99% of the potency of the antibody, or the antigen-binding portion thereof, prior to storage.

25. The pharmaceutical formulation claim **2**, wherein after 24 months of storage at 2-8° C., at least 96% of the antibody, or the antigen-binding portion thereof, has native conformation, at least 50% of the antibody, or the antigen-binding portion thereof, is the main charge variant, and/or the antibody retains at least 99% of the potency of the antibody, or the antigen-binding portion thereof, prior to storage.

26. The pharmaceutical formulation claim **2**, wherein after 24 months of storage at 2-8° C., at least 98% of the antibody, or the antigen-binding portion thereof, has native conformation, at least 55% of the antibody, or the antigen-binding portion thereof, is the main charge variant, and/or

the antibody retains at least 99% of the potency of the antibody, or the antigen-binding portion thereof, prior to storage.

27. A pharmaceutical formulation comprising (a) 60 mg/mL±10 mg/mL of an anti-human Activin A antibody, or antigen-binding portion thereof (b) 10 mM±2 mM histidine, pH 6.3±0.3, (c) 0.05%±0.025% polysorbate 20, (d) 70 mM±14 mM Arginine, and (e) 5%±1% sucrose, wherein the antibody, or the antigen-binding portion thereof, comprises an heavy chain variable region comprising SEQ ID NO: 7 and a light chain variable region comprising SEQ ID NO: 8.

28. The pharmaceutical formulation of claim **1**, wherein the formulation is contained in a container.

29. The pharmaceutical formulation of claim **28**, wherein the container is a vial.

30. The pharmaceutical formulation of claim **29**, wherein the vial is glass.

31. The pharmaceutical formulation of claim **30**, wherein the glass is Type 1 borosilicate glass with a FluroTec® coated 4432/50 butyl rubber stopper.

32. The pharmaceutical formulation of claim **1**, wherein the formulation is suitable for intravenous administration to a human subject in need thereof.

33. The pharmaceutical formulation of claim **1**, wherein the formulation is suitable for subcutaneous administration to a human subject in need thereof.

34. The pharmaceutical formulation of claim **1**, wherein the formulation is a liquid formulation.

35. The pharmaceutical formulation of claim **1**, wherein the formulation is a lyophilized formulation.

36. A kit comprising a pharmaceutical formulation of claim **1**, a container, and instructions of use thereof.

37. The kit of claim **36**, wherein the container is a glass vial fitted with a FluroTec® coated chlorobutyl stopper.

38. A method of treating a disease or disorder associated with Activin A activity, the method comprising administration of a therapeutically effective amount of the pharmaceutical composition of claim **1** to a subject in need thereof.

39. The method of claim **38**, wherein the disease or disorder associated with Activin A activity is Fibrodysplasia ossificans progressiva (FOP).

* * * * *